Saw a post here with a pretty cautious take on Novo Nordisk (NVO). Figured I’d throw in my perspective.

Yes, the stock is down about 42% this year. Earnings weren’t mind-blowing. There’s a CEO change. A lot of people are sitting on the sidelines.

But here’s the thing. The company isn’t broken. The price is.

You’re looking at a global pharma leader with:

• Dominance in GLP-1 (Ozempic, Wegovy)

• ROE over 80 percent

• PE around 13 after the drop

• Consistent revenue growth and strong free cash flow

• Dividend stability and no debt red flags

Some are saying the valuation doesn’t reassure them. That’s a price-driven reaction, not a fundamentals-based one. Fair enough if you’re a technical trader. But I’m not playing short-term games. I’m holding the business, not just the ticker.

As for the CEO change, it’s internal. Not some outsider disrupting operations. In pharma, the pipeline matters more than who’s wearing the suit.

If you’re waiting for a confirmed reversal, odds are you’ll be buying back in at a higher price. I’d rather sit through volatility than chase recovery later.

To me, this is simple. If you can’t handle short-term red, this isn’t your stock. If you understand what you’re holding, and you’re managing your risk, then this correction is a chance to accumulate, not panic.

Not advice. Just conviction.